Apellis is a clinical stage immunotherapy company and targets the complement pathways to correct auto-immune conditions. Apellis will seek to further explore the interface between complement and adaptive immunity in a range of indications, including paroxysmal nocturnal hemoglobinuria (PNH), chronic obstructive pulmonary disease (COPD) and AMD, as well as graft-versus-host disease (GvHD), ABO-incompatible transplantation, periodontitis and ischemia reperfusion injury.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/02/14 | $33,000,000 | Series C |
AJU IB Investment Epidarex Capital Morningside Group | undisclosed |
| 02/12/16 | $47,000,000 | Series D |
AJU IB Investment Cormorant Asset Management Epidarex Capital Hillhouse Capital Group Morningside Group VenBio | undisclosed |
